Avita Medical Inc Reports Q1 2025 Financial Results
Key points
- Total revenues of $18.5 million, up 67% year-over-year
- Gross profit margin of 84.7%, up from 86.4% in Q1 2024
- Net loss of $13.9 million, an improvement from $18.7 million in Q1 2024
Full summary
Avita Medical Inc, a regenerative medicine company, has reported its financial results for the quarter ended March 31, 2025. The company recorded total revenues of $18.5 million, up 67% from $11.1 million in the same period last year. Gross profit margin was 84.7%, compared to 86.4% in Q1 2024. Net loss was $13.9 million, an improvement from $18.7 million in the prior-year quarter. The company's sales and marketing expenses increased to $14.8 million, while general and administrative expenses decreased to $6.4 million, and research and development expenses increased to $6.3 million. Avita Medical ended the quarter with $14.9 million in cash and cash equivalents and $10.9 million in marketable securities.
Summary generated by a large language model. Please interpret with care.